Endothelial Repair Strategies for Residual Cardiovascular Risk

Abstract

Residual cardiovascular risk persists despite advances in lipid lowering and standard therapies, highlighting the need for novel approaches targeting endothelial dysfunction. This review explores the epidemiology, underlying mechanisms, clinical features, diagnostic strategies, and the latest evidence-based interventions for endothelial repair, emphasizing their clinical relevance and future potential in reducing cardiovascular events.

Introduction

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, even as therapeutic milestones such as statin therapy and antihypertensive agents have markedly reduced major adverse cardiovascular events. However, a significant proportion of patients continue to experience vascular events despite optimal risk factor management a phenomenon termed residual cardiovascular risk. Central to this issue is endothelial dysfunction, a hallmark of early atherosclerosis and a critical determinant of vascular health. Addressing endothelial injury and promoting endothelial repair have emerged as promising strategies to mitigate residual risk, necessitating a comprehensive understanding of underlying mechanisms, clinical implications, and evolving therapeutic options.

Epidemiology / Disease Burden

Despite aggressive primary and secondary prevention strategies, residual cardiovascular risk accounts for a substantial burden of myocardial infarction, stroke, and cardiovascular death. Epidemiological data indicate that up to 50% of patients with established atherosclerotic CVD experience recurrent events despite optimal LDL-cholesterol lowering. Endothelial dysfunction has been identified in approximately 70% of patients with coronary artery disease, serving as an independent predictor of adverse outcomes. The burden is particularly pronounced in high-risk populations, including patients with diabetes, chronic kidney disease, and those with a history of premature CVD.

Pathophysiology

The endothelium is a dynamic monolayer that regulates vascular tone, hemostasis, inflammation, and cellular adhesion. Endothelial dysfunction is characterized by reduced nitric oxide (NO) bioavailability, increased oxidative stress, and a pro-inflammatory, pro-thrombotic phenotype. These changes lead to impaired vasodilation, enhanced leukocyte adhesion, smooth muscle proliferation, and subsequent atherogenesis. Mechanisms contributing to endothelial injury include hyperlipidemia, hypertension, hyperglycemia, smoking, and chronic inflammation. Endothelial repair involves the mobilization of endothelial progenitor cells (EPCs), local endothelial cell proliferation, and paracrine signaling, all of which are impaired in patients with persistent residual risk.

Risk Factors

Traditional risk factors such as dyslipidemia, hypertension, diabetes mellitus, smoking, and obesity are well-established contributors to endothelial dysfunction. Non-traditional factors including chronic inflammation, oxidative stress, and genetic predispositions also impair endothelial repair capacity. Emerging data underscore the importance of factors such as elevated homocysteine, chronic kidney disease, and environmental toxins in perpetuating endothelial injury and limiting reparative processes.

Clinical Features

Endothelial dysfunction is typically subclinical but can manifest indirectly through impaired flow-mediated dilation (FMD), increased arterial stiffness, and microalbuminuria. Clinically, patients may present with angina, claudication, or symptoms related to impaired organ perfusion. Importantly, endothelial dysfunction is associated with a higher incidence of major adverse cardiovascular events, even in individuals without overt atherosclerotic disease, underscoring its significance as a therapeutic target.

Diagnosis

Assessment of endothelial function is challenging in routine clinical practice. Non-invasive techniques such as brachial artery FMD, peripheral arterial tonometry, and carotid intima-media thickness provide surrogate markers of endothelial health. Circulating biomarkers including NO metabolites, asymmetric dimethylarginine (ADMA), and levels of EPCs offer additional insights but are not yet standardized for widespread clinical use. Invasive methods, such as coronary endothelial function testing, are reserved for research and select clinical scenarios.

Treatment & Management

Current management strategies for endothelial dysfunction focus on aggressive modification of traditional risk factors. Statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers have demonstrated endothelial protective effects independent of their primary indications. Lifestyle interventions including smoking cessation, weight reduction, regular physical activity, and dietary modifications consistently improve endothelial function. Glycemic control in diabetes and blood pressure optimization are critical components of comprehensive risk reduction.

Recent Advances / Emerging Therapies

Recent advances in endothelial repair strategies include the investigation of agents that enhance EPC mobilization and function, such as statins, PPAR agonists, and GLP-1 receptor agonists. Novel therapies targeting oxidative stress (e.g., NADPH oxidase inhibitors), anti-inflammatory pathways (e.g., colchicine, IL-1β inhibitors), and microRNAs regulating endothelial regeneration are under active investigation. Cell-based therapies, including autologous EPC transplantation and exosome-based interventions, have shown promise in preclinical and early clinical studies. Additionally, pharmacological interventions such as SGLT2 inhibitors and PCSK9 inhibitors are being evaluated for their potential to augment endothelial repair and reduce residual risk beyond lipid lowering.

Guideline Recommendations

Contemporary guidelines emphasize the importance of comprehensive risk factor modification as the cornerstone of endothelial protection. While specific therapies targeting endothelial repair are not yet standard of care, emerging evidence supports the integration of novel agents with demonstrated vascular benefits in high-risk populations. Ongoing trials and future guideline updates are expected to clarify the role of endothelial-targeted therapies in mainstream clinical practice.

Conclusion

Residual cardiovascular risk due to endothelial dysfunction remains a critical clinical challenge. Advances in understanding the mechanisms of endothelial injury and repair have paved the way for novel therapeutic strategies aimed at restoring vascular health. While traditional risk factor modification remains foundational, emerging pharmacological and cell-based therapies hold promise for reducing residual risk and improving outcomes in high-risk patients. Continued translational research and rigorous clinical trials are essential to define the optimal integration of these strategies into evidence-based cardiovascular care.